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Abstract
Abstract: The application of emerging nanotechnology to the practice of medicine represents a frontier of
nanomedicine. Nanomedicine has been defined as a science which emphasizes the use of nanoscale tools in
conjunction with background knowledge of the human body for medical diagnosis and treatment. Application of
nanomedicine in EM may give EM providers the opportunity to diagnose and treat life-threatening diseases in a
shorter period of time. These applications include diagnostic utilities, preventive medicine, targeted
pharmacotherapy, and tissue regeneration.
The concept of nanotechnology arose in the 1950s with
Feynman’s vision that engineering could occur on an
atomic level [1]. In the 1980s, Drexler predicted the revolu-
tionizing of traditional manufacturing models with highly
efficient and precise nanoscale processes [2]. Presently, the
National Nanotechnology Initiative states that nanotechnol-
ogy involves the manipulation of matter with dimensions
between 1 and 100 nanometers to promote innovation
across multiple disciplines. Myriad applications of nano-
technology already exist for the manufacture of consumer
products, such as the incorporation of lightweight nanoma-
terials with dent-, scratch-, stain-, and wrinkle-resistant
properties into automobiles, sports equipment, and cloth-
ing [3]. Nanotechnology also has promissing energy app-
lications, as smaller lithium ion batteries capable of rapidly
charging and discharging could increase the efficiency of
mobile devices and electric automobiles [4]. Although still
at a nascent stage, development of nanotechnology may
lead to profound advances in manufacturing, the sciences,
and medicine.
The application of emerging nanotechnology to the
practice of medicine represents a frontier of nanomedi-
cine. Nanomedicine has been defined as a science which
emphasizes the use of nanoscale tools in conjunction with
background knowledge of the human body for medical
diagnosis and treatment [5]. By operating at molecular,
intracellular, and intercellular levels, nanomedicine offers
promising improvements in diagnostic utilities, preventive
medicine, targeted pharmacotherapy, tissue regeneration,
etc. Although largely theoretical at present, such potential
improvements have significant implications for clinical
practice of emergency medicine (EM).
Nanodiagnostic medicine
Point-of-care testing: EM providers use point-of-care testing
to promote rapid clinical decision-making and appropriate
triage, thereby increasing emergency department (ED)
throughput. These include tests for glucose, electrolytes,
renal function, blood gas, pregnancy, cardiac biomarkers,
and infectious diseases. Nanoscale technology allows for the
development of highly sensitive point-of-care detection
devices. For example, a recently developed microfluidic
device with a surface plasmon resonance system demon-
strated considerable sensitivity in its ability to measure a
B-type natriuretic peptide concentration of 5 pg/mL [6].
Floriano et al. have suggested that using saliva-based
nano-biochip tests for cardiac biomarkers in concert with
electrocardiography could augment rapid diagnosis of and
screening for acute myocardial infarction [7]. In addition,
an assay for bacterial meningitis using quantum dots
(Q-dots) could detect low levels of pathogen from a blood
specimen, making possible earlier administration of anti-
biotics [8]. Zhao et al. have described a method of using a
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bioconjugated nanoparticle-based bioassay to detect a sin-
gle bacterium within 20 minutes [9]. The greater sensitiv-
ity of nanomedicine point-of-care tests would therefore
enable EM providers to more accurately and expeditiously
diagnose and hence treat disease.
Neurologic disease: Magnetic resonance imaging (MRI)
is a powerful tool for diagnosis of structural central ner-
vous system pathology [10]. A nanoparticle-based MRI
contrast agent could enhance visualization of structural or
vascular abnormalities, such as in Parkinson’s disease or
cerebrovascular accidents (CVAs). This method could im-
prove the quality of noninvasive anatomic imaging to be
on par with that of histological examination [11].
Cardiovascular diseases: Applications of nanomedicine
in cardiovascular diseases include diagnosis and treatment
of atherosclerosis and decreasing re-stenosis rates after
stenting. An advantage of using a nanoscale agent is early
detection of disease [12]. Although there are many applica-
tions for the diagnosis of cardiovascular disease based on
nanoparticulate agents investigators in this field of medi-
cine are starting to use nanomedicine to deliver therapeutic
agents [13]. An exciting application is the nanopatterning
and nanostructuring of stents makes these stents commu-
nicate with cells at nanoscale levels. This application will
allow the endothelium to grow over the sent and will cre-
ate an area of future research on obstructing coronary ar-
tery disease [14,15].
Pharmacotherapy
Nanomedicine offers several strategies for improving the
efficiency of pharmacotherapy. Encapsulating relatively in-
soluble pharmaceuticals in liposomes or micelles enhances
drug solubility in the bloodstream [8,16]. These transport
vehicles, exhibiting a hydrophobic core and a hydrophilic
exterior, also shield toxic pharmaceuticals from an immune
response, resulting in less degradation via phagocytosis
[8,17]. Conjugation of pharmaceuticals to dendrimers, or
artificial proteins, achieves similar results, and with the
addition of site-specific surface antibodies, also allows for
targeted drug delivery, resulting in decreased systemic ad-
verse effects [16]. This strategy has demonstrated efficacy
in the treatment of arthritis in rats utilizing conjugated
indomethacin, with sites of inflammation targeted by a fac-
tor of 2.29 compared with unconjugated indomethacin
[18]. Overall, application of nanotechnology to pharma-
cotherapy (e.g., analgesic, antibiotic, thrombolytic, etc.)
improves drug bioavailability and potency, while reducing
adverse effects.
These numerous benefits are evident when applied to
the treatment of ischemic CVA in the ED. Ischemic CVA
is a source of significant morbidity and mortality in the
United States [19]. To restore cerebrovascular perfusion,
eligible patients may receive an intravenous thrombolytic
therapy, although it carries with it a risk of hemorrhagic
complications. To temper this risk, Lanza et al. have ad-
vocated employing a lipid-encapsulated perfluorocarbon
nanoparticle for thrombolytic delivery [20]. Its scale would
limit it to the intravascular space, thereby minimizing ex-
travasation of thrombolytic and resultant hemorrhagic
complication. The efficiency of such a drug delivery mech-
anism would allow for a 10–100 times reduction in
thrombolytic dosage, thus further decreasing the risk of
hemorrhagic complication. In addition, Morrow et al. pro-
posed utilizing perfluorocarbon nanoparticle emulsions
with surface antibodies to cross-linked fibrin to target
thrombi for vascular MRI, a concept which could translate
to targeted thrombolytic delivery as well [17].
Miscellaneous applications
Morrow et al. have anticipated the concept of a nanoma-
chine, nanoscale technology which would target lesions
(e.g., neurologic, cardiovascular) within a patient to modify
pathophysiology at the molecular level [17]. In patients
suffering from hemorrhagic CVA, prolonged arterial ex-
travasation in the acute phase adversely affects the potential
for reperfusion, as the blood brain barrier becomes more
permeable via inflammatory mediators [8]. Ellis-Behnke
have suggested a mechanism of lining injured cerebral
arteries with a molecular coating to counter this process
[8]. Haase has advocated an alternative strategy in the treat-
ment of sepsis, the severe form of which results in nearly
600,000 ED visits annually [21,22]. In septic shock, an ab-
normal inflammatory response to circulating bacterial
endotoxin results in greater vascular permeability and
hence decreased tissue perfusion [23]. Nanotechnology
could target and eliminate the cytokines which mediate this
deranged systemic response, effectively functioning as a
blood filtering system [21].
The future may see the synthesis of novel nanomaterials
for acute management of trauma (e.g., burns, fractures) in
the ED. Being biologically inert and hence less antigenic,
use of these nanomaterials in tissue regeneration may
eliminate the need for organic grafts and transplants,
which are subject to compatibility and supply limitations
[18]. In a hamster model, Ellis-Behnke has demonstrated
the feasibility of using a synthetic extracellular matrix
scaffold for neural regeneration of the visual tract. Similarly,
carbon nanotubes show promise as a framework for bone
regeneration [8]. Furthermore, these nanomaterials may be
engineered to exhibit antibacterial surfaces, which may re-
duce the incidence of nosocomial infection [21]. These
applications could be extended to experimental treatment
of diabetic neuropathy and as well to eliminate colitis in
rats [24,25].
Applications of nanomedicine in EM may give physi-
cians’ opportunity to detect and treat life-threatening dis-
eases in short period of time. These applications include
Pourmand et al. DARU Journal of Pharmaceutical Sciences 2012, 20:26 Page 2 of 3
http://www.darujps.com/content/20/1/26
diagnostic utilities, preventive medicine, targeted pharma-
cotherapy, and tissue regeneration. -It is worthwhile to
mention that there are still some concerns regarding nano-
particles' functionality and their characteristics in vivo ver-
sus in vitro.
Competing interests
The authors have no commercial associations or sources of support that
might pose a conflict of interest.
Authors’ contribution
All authors have made substantive contributions to the study, and all authors
endorse the data and conclusions. All authors read and approved the final
manuscript.
Author details
1Department of Emergency Medicine, George Washington University Medical
Center, 2150 Pennsylvania, Ave NW, Suite 2B, Washington, DC 20037, USA.
2Biotechnology Research Center, Tehran University of Medical Sciences,
Tehran, Iran.
Received: 6 July 2012 Accepted: 10 July 2012
Published: 10 September 2012
References
1. Feynman RP: There’s plenty of room at the bottom. Eng Sci (Caltech) 1960,
23:22–36.
2. Drexeler KE: Nanosystems: Molecular Machinery, Manufacturing, and
Computation; 2006. http://www.e-drexler.com/d/06/00/ Nanosystems/toc.
html. ISBN ISBN 0-471-57518-6.
3. National Nanotechnology Initiative: What it is and how it works; 2011.
Available at: http://www.nano.gov/. Accessed June 20, 2011.
4. Kang B, Ceder G: Battery materials for ultrafast charging and discharging.
Nature 2009, 458:190–193.
5. Duncan R: Nanomedicines in action. Pharm J 2004, 273:485–488.
6. Wei C, Nagai T, Wei W, Nemoto T, Awais M, Niwa O, et al: New advances in
nanomedicine: Diagnosis and preventive medicine. Med Clin North Am
2007, 91:871–879.
7. Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG,
et al: Use of saliva-based nano-biochip tests for acute myocardial
infarction at the point of care: a feasibility study. Clin Chem 2009,
55:1530–1338.
8. Ellis-Behnke R: Nano neurology and the four P’s of central nervous
system regeneration: Preserve, permit, promote, plasticity. Med Clin North
Am 2007, 91:937–962.
9. Zhao X, Hilliard LR, Mechery SJ, Wang Y, Bagwe RP, Jin S, et al: A rapid
bioassay for single bacterial cell quantitation using bioconjugated
nanoparticles. Proc Natl Acad Sci USA 2004, 101:15027–15032.
10. McRobbie DW, Moore EA, Graves MJ, Prince MR: MRI from Picture to Proton.
Cambridge: Cambridge University Press; 2002:17–45.
11. Na HB, Lee JH, An K, Park YI, Park M, Lee IS, et al: Development of a T1
contrast agent for magnetic resonance imaging using MnO
nanoparticles. Angew. Chem Int Ed Engl 2007, 46:5397–5401.
12. Jaffer FA, Libby P, Weissleder R: Molecular and cellular imaging of
atherosclerosis: Emerging applications. J Am Coll Cardiol 2006,
47:1328–1338.
13. McCarthy JR: Nanomedicine and Cardiovascular Disease. Curr Cardiovasc
Imaging Ref 2010, 3:42–49.
14. Yu SS, Ortega RA, Reagan BW, McPherson JA, Sung HJ, Giorgio TD, et al:
Emerging applications of nanotechnology for the diagnosis and
management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev
Nanomed Nanobiotechnol 2011, 3:620–646.
15. Shafiee H, Mohammadi H, Rezayat SM, Hosseini A, Baeeri M, Hassani S, et al:
Prevention of malathion-induced depletion of cardiac cells
mitochondrial energy and free radical damage by a magnetic
magnesium-carrying nanoparticle. Toxicol Mech Methods 2010,
20(9):538–543.
16. Wei C, Wei W, Morris M, Kondo E, Gorbounov M, Tomalia DA:
Nanomedicine and drug delivery. Med Clin North Am 2007, 91:863–870.
17. Morrow KJ, Bawa R, Wei C: Recent advances in basic and clinical
nanomedicine. Med Clin North Am 2007, 91:805–843.
18. Brewer M, Zhang T, Dong W, Rutherford M, Tian ZR: Future approaches of
nanomedicine in clinical science. Med Clin North Am 2007, 91:963–1016.
19. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al:
Heart disease and stroke statistics-2011 update. Circulation 2011,
123:e18–e209.
20. Lanza GM, Marsh JN, Hu G, Scott MJ, Schmieder AH, Caruthers SD, et al:
Rationale for a nanomedicine approach to thrombolytic therapy. Stroke
2010, 41(suppl):42–44.
21. Morris K: Nanotechnology crucial in fighting infectious disease. Lancet
Infect Dis 2009, 9:215.
22. Wang HE, Shapiro NI, Angus DC, Yealy DM: National estimates of severe
sepsis in United States emergency departments. Crit Care Med 2007,
35:1928–1936.
23. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al:
Surviving sepsis campaign: International guidelines for management of
severe sepsis and septic shock. Crit Care Med 2008, 36:296–327.
24. Miroliaee A, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, Abdollahi M:
Amelioration of experimental colitis by a novel nanoselenium-silymarin
mixture. Toxicol Mech Methods 2011, 21(3):200–208.
25. Hosseini A, Sharifzadeh M, Rezayat SM, Hassanzadeh G, Hassani S, Baeeri M,
et al: Benefit of magnesium-25 carrying porphyrinfullerene nanoparticles
in experimental diabetic neuropathy. Int J Nanomedicine 2010, 5:517–523.
doi:10.1186/2008-2231-20-26
Cite this article as: Pourmand et al.: Application of nanomedicine in
emergency medicine; Point-of-care testing and drug delivery in twenty
- first century. DARU Journal of Pharmaceutical Sciences 2012 20:26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pourmand et al. DARU Journal of Pharmaceutical Sciences 2012, 20:26 Page 3 of 3
http://www.darujps.com/content/20/1/26
